Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, has announced the 36-month results from its Phase 1/2a clinical study of RG6501 (OpRegen) for patients with geographic atrophy secondary to age-related macular degeneration. These results were presented at the Clinical Trials at the Summit 2025 by Dr. Christopher D. Riemann. The study demonstrated mean vision gains of +9 letters in patients who received extensive coverage of OpRegen cell therapy at the lesion site, with evidence of retinal structural improvement persisting for three years. This suggests anatomical and functional improvements following a single administration of the therapy. Additionally, the Phase 2a "GAlette study," which is evaluating the subretinal delivery of OpRegen cell therapy, is currently enrolling participants.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。